How does Entresto (sacubitril/valsartan) affect serum potassium and sodium levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Entresto's Effect on Electrolytes

Entresto (sacubitril/valsartan) causes hyperkalemia in approximately 12-18% of patients and hypotension in 18% of patients, while having minimal to no clinically significant effect on serum sodium levels. 1

Potassium Effects

Incidence and Magnitude

  • Hyperkalemia (K+ >5.5 mEq/L) occurs in approximately 16-18% of patients treated with Entresto, which is similar to or slightly lower than enalapril (16%) and valsartan alone (20%) 1
  • In the PARADIGM-HF trial, hyperkalemia rates were comparable between Entresto and enalapril (12% vs 14% as adverse reactions) 1
  • Severe hyperkalemia (K+ >6.0 mEq/L) is actually LESS common with Entresto than with ACE inhibitors, particularly when combined with mineralocorticoid receptor antagonists (MRAs) 2

Clinical Context

Entresto is listed among drugs that decrease potassium excretion and can cause hyperkalemia 3. However, the neprilysin inhibition component appears to provide a protective effect against severe hyperkalemia compared to traditional RAAS inhibitors. When patients on MRAs were switched to Entresto, severe hyperkalemia occurred at 2.3 per 100 patient-years versus 3.3 per 100 patient-years with enalapril 2.

Special Populations

In anuric hemodialysis patients, Entresto increased mean serum potassium from 4.84 to 5.04 mmol/L over 6 months, but severe hyperkalemia remained uncommon (4.2% at 6 months), suggesting relative safety even in this high-risk population 4.

Sodium Effects

Minimal Clinical Impact

Serum sodium levels are NOT significantly affected by Entresto in most patients 5. Despite the drug's natriuretic effects (increased sodium excretion), this does not translate to clinically significant hyponatremia in the majority of cases.

Rare Hyponatremia

While case reports of Entresto-induced hyponatremia exist 6, this is uncommon. The drug actually increases natriuresis and diuresis acutely (first 24 hours), particularly in salt-sensitive hypertension, but this effect diminishes by day 28 5.

Blood Pressure Effects

Hypotension is the most common electrolyte-related adverse effect, occurring in 18% of patients (compared to 12% with enalapril) 1. This manifests as:

  • Orthostasis in 2.1% of patients
  • Falls in 1.9% of patients
  • Dizziness in 6% of patients

Monitoring Algorithm

Check potassium and creatinine:

  • At baseline
  • Within 1-2 weeks of initiation
  • After each dose uptitration
  • At 1,3,6, and 12 months, then periodically

Hold or reduce dose if:

  • K+ >5.5 mEq/L (consider holding)
  • K+ >6.0 mEq/L (hold and address)
  • Symptomatic hypotension
  • Creatinine increase >50% from baseline

Drug Interactions Increasing Hyperkalemia Risk

Concomitant use with these agents increases hyperkalemia risk 1:

  • Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)
  • Potassium supplements
  • Salt substitutes containing potassium
  • NSAIDs
  • Other RAAS inhibitors (contraindicated with ACE inhibitors; avoid with other ARBs)

Key Clinical Pitfalls

  1. Don't avoid Entresto solely due to hyperkalemia concerns - the risk is similar to or lower than traditional RAAS inhibitors, and the mortality benefit is substantial
  2. The neprilysin inhibition component actually provides relative protection against severe hyperkalemia compared to ACE inhibitors, especially when combined with MRAs 2
  3. Hyponatremia is rare despite increased natriuresis - don't over-monitor sodium unless clinically indicated
  4. Hypotension is more common than electrolyte abnormalities - counsel patients about orthostatic symptoms and falls risk

Related Questions

In a patient on sacubitril/valsartan (Entresto) who develops a serum potassium of 5.4 mEq/L, what management steps should be taken?
How to manage hyperkalemia in a patient taking valsartan?
Can Entresto (sacubitril/valsartan) cause hypernatremia?
In a 75-year-old patient with serum potassium of 5.6 mmol/L and normal renal function, should the valsartan dose be reduced?
How should I manage a patient taking torsemide and Entresto (sacubitril/valsartan) who has a serum potassium of 3.4 mmol/L?
What gastrointestinal conditions could be causing a female patient's right lower quadrant pain and constipation that worsen with menses?
Can tramadol be used safely during pregnancy, and what are the recommended dosing limits and monitoring guidelines?
In a male patient with bone‑only metastatic castration‑resistant prostate cancer who has received docetaxel, continuous androgen deprivation therapy with orchiectomy, long‑term abiraterone, targeted radiation, a single dose of sipuleucel‑T (Provenge) discontinued due to allergy, and three cycles of Lu‑177‑PSMA‑617 (Pluvicto), and who started the investigational androgen‑receptor ligand‑directed degrader BMS‑986460 (1 mg daily) with an initial PSA rise followed by decline to 13.06 ng/mL and a recent 19 % increase to 15.6 ng/mL, castrate testosterone, stable hematologic parameters, and molecular findings of AR amplification, TP53 rearrangement, and CHEK2 alteration, is he still deriving clinical benefit from BMS‑986460 or is he developing emerging resistance?
What is the best medication for vaginal dryness in a 77-year-old postmenopausal female?
What are the appropriate dosing, contraindications, monitoring parameters, and alternative options for morphine in an adult opioid‑naïve patient with acute severe pain?
Why am I still unable to sleep while taking buspirone 10 mg and trazodone 25 mg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.